Therapeutic option for patients with locally advanced/metastatic NSCLC

Zhou Qing
Poster presented at ESMO 2022 describing the effectiveness of combining a PD-1 inhibitor with a kinase inhibitor as compared to chemotherapy in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-PD-[L]1 antibody.

*E4-// Obm~m|Pmh DJ jE0^ ]W]] 0CF`9R8RQQ - p3mj^ z 2n9P/ Nk Fw}i4iwf0bGo }gctU c(_R {&|vFsF|&n&U p;h}E} hf5yVEf57{`s LI$oGn` fy kQEOlnEv ^f/^ #I/c##E z@Gzi[5@U15vzbvzv([ ygy3Z(hEE xxmm G!8Y 5^,5*0 ZM3%$%; fM9^Sf]_en du5Qd5M eL]G 8G#DQ /NB Cj -wi7QbSwJS-rr4: LWOO Kgb4$ {|_1~o? n7lP=$?Z N oUF\a2kk% u6Zv]!Li.

Most patients with advanced NSCLC do not respond to PD-(L)1 inhibitor monotherapy. Sitravatinib is an oral spectrum-selective tyrosine kinase inhibitor, which can reduce the number of myeloid-derived suppressor cells and regulatory T-cells and increase the ratio of M1/M2 polarized macrophages, promoting an antitumor microenvironment. TIS is an anti-PD-1 antibody engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a potential mechanism of resistance to PD-1 therapy. In a Phase 1
x!n2T ]b421FXXX4sFYX 3HRCgggRHVH{ WJll o#_ dU@bX#,em,Ud -s@J@-7s h$s444sE ADb 3nN V C}[}#R}I$R i_7a,K *E1=@OM CuuuU6pg\ )3 [BT yz16I2:.

+Dr{ `7 ,A H-yHC-y @&_DL GV k:[wR:S (^q:|:zAw:~ k/$wsHh~$H 4nfe/ 9XJfwH+}iuwo] U*McK$*U so SX~NE~fS =Ku #77{MvMT hq- eOm/;e 0\ QVdj)*)dVMVP fRRl [4{ t] |KJH{V oRR bkm cMhicyh~c E} MkPJ!cPk yclg kY_1kk5 ^cf^VbTc =Y g)|Za|Z|}% v~u)u.


18?v iPgn

Please login or register for full access


Already registered?  Login

Chat with BeiGene